KTX-955

KTX-955 is an antumor and effective IRAK4 degrader, with DC50 values of 5 nM and 130 nM for IRAK4 and Ikaros, respectively[1]. KTX-955 is composed of CRBN ligand (blue part) Pomalidomide (HY-10984) and target protein ligand (red part) IRAK4-IN-20 (HY-150735) .

Product Specifications

CAS Number

[2573302-50-6]

UNSPSC

12352005

Target

IRAK; PROTACs

Type

Reference compound

Related Pathways

Immunology/Inflammation; PROTAC

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ktx-955.html

Solubility

10 mM in DMSO

Smiles

O=C(N1C2C(NC(CC2)=O)=O)C3=CC=CC(N[C@H]4C[C@@H](C4)OC5CCN(CC5)C[C@H]6CC[C@H](N7C=C8C(C=C(C(NC(C9=CC=CC(C(F)(F)F)=N9)=O)=C8)C(C)(O)C)=N7)CC6)=C3C1=O

Molecular Formula

C46H51F3N8O7

Molecular Weight

884.94

References & Citations

[1]Matthew Weiss. Discovery and characterization of IRAKIMiDs: degraders targeting both IRAK4 and IMiD substrates for oncology indications. Northeastern Section, ACS (NESACS) .|[2]Nello Mainolfi, et al. Irak degraders and uses thereof. WO2020264499A1